Study of Lademirsen (SAR339375) in Patients With Alport Syndrome

NCT02855268 · clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
43
Enrollment
INDUSTRY
Sponsor class

Stopped The results of the futility analysis led to the study termination. No unexpected safety findings were identified.

Conditions

Interventions

Sponsor

Genzyme, a Sanofi Company